Methotrexate subcutaneous auto-injection - Medac Pharma

Drug Profile

Methotrexate subcutaneous auto-injection - Medac Pharma

Alternative Names: Methotrexate ready-to-use autopen; Metoject® prefilled pen; Metojet® PEN; MPI-2505; Rasuvo; Subcutaneous injectable MTX - Medac Pharma

Latest Information Update: 13 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medac; Medac Pharma
  • Developer Medac Pharma
  • Class Abortifacients; Antiasthmatics; Antineoplastics; Antipsoriatics; Antirheumatics; Benzamides; Disease-modifying antirheumatics; Glutamates; Pterins; Small molecules
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Juvenile rheumatoid arthritis; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 09 Feb 2018 Patent Trial And Appeal Board (PTAB) upholds all claims related '231 patent covering the use of methotrexate solution for the treatment of rheumatoid arthritis in USA
  • 06 Oct 2014 Launched for Rheumatoid arthritis, Psoriasis and Juvenile rheumatoid arthritis in USA (SC) - first global launch
  • 01 Aug 2014 medac GmbH completes a clinical trial in Juvenile rheumatoid arthritis in USA (NCT02052167)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top